Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 240-249

  Takano, Tomoko ^a   Cybulsky, Andrey V ^a   Cupples, William A ^b   Ajikobi, David O ^b   Papillon, Joan ^a   Aoudjit, Lamine ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; COMPLEMENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INDOMETACIN; INULIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; THROMBOXANE A2 DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; EPITHELIUM CELL; GLOMERULUS; HEYMANN NEPHRITIS; IMMUNE RESPONSE; INULIN CLEARANCE; KIDNEY FUNCTION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEINURIA; RAT; TREATMENT OUTCOME; UPREGULATION;

ACTINS; ANIMALS; COMPLEMENT SYSTEM PROTEINS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; EICOSANOIDS; EPITHELIAL CELLS; FURANS; GLOMERULAR FILTRATION RATE; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; INDOMETHACIN; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE A2;

EID: 0037379945     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043604     Document Type: Article

References (40)

1. Bek M, Nusing R, Kowark P, Henger A, Mundel P, and Pavenstadt H (1999) Characterization of prostanoid receptors in podocytes. J Am Soc Nephrol 10:2084-2093.
2. Blume C, Heise G, Muhlfeld A, Back D, Schror K, Gerhardz CD, Grabensee B, and Heering P (1999) Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 56:1770-1778.
3. 2: function and pharmacological regulation. Biochem Pharmacol 36:2429-2436.
4. Chanmugam P, Heng L, Liou S, Jang BC, Boudreau M, Yu G, Lee JH, Kwon HJ, Beppu T, Yoshida M, et al. (1995) Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophage stimulated with lipopolysaccharide and in experimental glomerulonephritis. J Biol Chem 270:5418-5426.
5. Cupples WA and Sonnenberg H (1987) Renal medullary plasma flow rate and reabsorption of salt and water from inner medullary collecting duct. Can J Physiol Pharmacol 65:2415-2421.
6. Cybulsky AV, Foster MH, Quigg RJ, and Salant DJ (2000a) Immunologic mechanisms of glomerular disease, in The Kidney (Seldin DW and Giebisch G eds) pp 2645-2697, Lippincott-Raven Publishers, Philadelphia.
7. 2 in glomerular epithelial cells. Am J Physiol 269:F739-F749.
8. 2 activation in experimental membranous nephropathy. Kidney Int 57:1052-1062.
9. Goeckeler ZM and Wysolmerski RB (1995) Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization and myosin phosphorylation. J Cell Biol 130:613-627.
10. Harris RC, McKanna JA, Akai Y, Jacobson HR, and DuBois RN (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510.
11. Heise G, Grabensee B, Schror K, and Heering P (1998) Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron 80:220-226.
12. 2 in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 9:408-416.
13. Hornbeck P (1997) Enzyme-linked immunosorbent assays, in Current Protocol in Immunology (Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, and Strober Q eds) vol I, pp 2.1, Wiley Interscience, New York.
14. Iniguez MA, Punzon C, and Fresno M (1999) Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 163:111-119.
15. Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108:1583-1587.
16. Komhoff M, Grone H-J, Klein T, Seyberth HW, and Nusing RM (1997) Localization of cyclooxygenase-1 and 2 in adult and fetal human kidney: implication for renal function. Am J Physiol 272:F460-F468.
17. 2-protein kinase A signaling and protein phosphatases-1 and -2A regulate human head and neck squamous cell carcinoma motility, adherence and cytoskeletal organization. Prostaglandins 51:35-48.
18. Marx J (2001) Cancer research. Anti-inflammatories inhibit cancer growth-but how? Science (Wash DC) 291:581-582.
19. McCarthy ET and Sharma M (2002) Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney Int 61:534-541.
20. 2 synthase inhibitor, on passive Heymann nephritis in rats. Eur J Pharmacol 316:73-80.
21. Nicoll-Griffith DA, Falgueyret JP, Silva JM, Morin P-E, Trimble L, Chan CC, Clas S, Leger S, Wang Z, Yergey JA, et al. (1999) Oxidative bioactivation of the lactol prodrug of a lactone cyclloxgyenase-2 inhibitor. Drug Metab Dispos 27:403-409.
22. Otto JC and Smith WL (1995) Prostaglandin endoperoxide synthase-1 and 2. J Lipid Mediators Cell Signalling 12:139-156.
23. Phipps RP, Pollock SJ, Kaur K, Kaufman J, Borrello MA, Graf BA, Nazarenko D, Roberts LJ, Morrow JD, Palis J, et al. (2000) Expression of cyclooxygenase-2 and prostaglandins by B-1 cells and B-CLL cells. Curr Top Microbiol Immunol 252:293-300.
24. Pierce KL, Fujino H, Srinivasan D, and Regan JW (1999) Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J Biol Chem 274:35944-35949.
25. Quigg RJ, Cybulsky AV, Jacobs JB, and Salant DJ (1988) Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells. Kidney Int 34:43-52.
26. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, et al. (1997) Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121:105-117.
27. Rossat J, Maillard M, Nussberger J, Brunner HR, and Burnier M (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76-84.
28. Schneider A and Stahl RA (1998) Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives. Nephrol Dial Transplant 13:10-12.
29. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC (1998) Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313-13318.
30. Takano T and Cybulsky AV (2000) Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells: role of cyclooxygenase-1 and -2. Am J Pathol 156:2091-2101.
31. Tegeder I, Pfeilschifter J, and Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057-2072.
32. Tischer DG and Couser WG (2000) Milestones in nephrology. [Heymann W, Hackel DB, Harwood S, Wilson SGF, and Hunter JLP (1951) Production of nephrotic syndrome in rats by Freund's adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 180:660.] [classical article]. J Am Soc Nephrol 11:183-188.
33. Topham PS, Haydar SA, Kuphal R, Lightfoot JD, and Salant DJ (1999) Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 55:1763-1775.
34. Wang JL, Cheng HF, Shappell S, and Harris RC (2000) A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57:2334-2342.
35. Wang JL, Cheng HF, Zhang MZ, McKanna JA, and Harris RC (1998) Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 275:F613-F622.
36. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, and Vane JR (1999) Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563-7568.
37. Weise WJ, Natori Y, Levine JS, O'Meara YM, Minto AW, Manning EC, Goldstein DJ, Abrahamson DR, and Salant DJ (1993) Fish oil has protective and therapeutic effects on proteinuria in passive Heymann nephritis. Kidney Int 43:359-368.
38. Yang RS, Fu WM, Wang SM, Lu KS, Liu TK, and Lin-Shiau SY (1998) Morphological changes induced by prostaglandin E in cultured rat osteoblasts. Bone 22:629-636.
39. Yuan H, Takeuchi E, Taylor GA, McLaughlin M, Brown D, and Salant DJ (2002) Nephrin dissociates from actin and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 13:946-956.
40. Zhang MZ, Wang JL, Cheng HF, Harris RC, and McKanna JA (1997) Cyclooxygenase-2 in rat nephron development. Am J Physiol 42:F994-F1002.